drugset / Trial / NCT05345210

Vonoprazan Hp Dual or Triple Eradication Regimes

NCT05345210

Phase 4 Unknown 500 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of dual or triple regimes for Helicobacter Pylori eradication using Vonoprazan as the antiacid agent.

Timeline

Start
2022-04-25
Primary completion
2023-02-28
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 1000 mg Oral
Comparator Clarithromycin Small molecule 500 mg Oral
Subject Furazolidone Small molecule 100 mg Oral
Subject Tetracycline Unknown 500 mg Oral
Comparator Vonoprazan Other / unclassified 20 mg Oral